Research from the 2025 ASCO Annual Meeting showed encouraging survival outcomes with second-line lurbinectedin for extensive-stage non-small cell lung cancer.
The post Real-World Data Affirms Second-Line Therapy’s Efficacy in ES-SCLC first appeared on Physician’s Weekly.
